Related Experiment Video
Updated: Jul 1, 2025

Preparation of Herbal Medicine: Er-Xian Decoction and Er-Xian-containing Serum for In Vivo and In Vitro Experiments
Published on: May 31, 2017
Comparative efficacy of Chinese herbal injections in patients with cardiogenic shock (CS): a systematic review and
Linkai Yue1,2, Lu Xiao1,2, Xuemin Zhang1,2
1Department of Emergency, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Chinese herbal injections (CHIs) combined with Western medicine (WM) significantly improve outcomes for patients with cardiogenic shock (CS). Shenmai injection (Sm) demonstrated excellent efficacy, particularly in reducing in-hospital mortality and improving key hemodynamic indicators.
Area of Science:
- Cardiology
- Pharmacology
- Integrative Medicine
Background:
- Cardiogenic shock (CS) is a critical complication of acute myocardial infarction, leading to high mortality.
- Chinese herbal injections (CHIs) are increasingly utilized in China as a therapeutic option for CS.
- Optimal CHI selection for CS treatment requires further investigation.
Purpose of the Study:
- To compare the efficacy and safety of various CHIs when used as adjunct therapy to Western medicine (WM) for CS.
- To identify the most effective CHI for improving patient outcomes in CS.
- To rank CHIs based on their impact on mortality and hemodynamic parameters.
Main Methods:
- A Bayesian network meta-analysis (NMA) was performed on data from 43 randomized controlled trials (RCTs) involving 2,707 participants.
- Six CHIs were evaluated: Shenfu injection (SF), Shengmai injection (SM), Shenmai injection (Sm), Danshen injection (DS), Huangqi injection (HQ), and Xinmailong injection (XML).
- Interventions were ranked using Surface Under the Cumulative Ranking Curve (SUCRA) probabilities; clustering analysis was used for outcome comparison.
Main Results:
- Shenmai injection (Sm) and Shenfu injection (SF) showed superior efficacy over WM alone in reducing in-hospital mortality.
- Sm + WM ranked highest for in-hospital mortality, cardiac index (CI), and hourly urine output, and second for left ventricular ejection fraction (LVEF) and mean arterial pressure (MAP).
- SF + WM demonstrated the highest clinical effective rate, while SM + WM led in improving MAP. Adverse drug reactions were reported in 31.8% of studies across five CHIs.
Conclusions:
- The combination of CHIs and WM offers significant advantages over WM alone for patients with CS.
- Shenmai injection (Sm) emerged as a highly effective CHI, excelling in reducing mortality and improving multiple hemodynamic outcomes.
- Further research into the safety profiles and optimal application of CHIs in CS management is warranted.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

